Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01294566




Registration number
NCT01294566
Ethics application status
Date submitted
3/02/2011
Date registered
11/02/2011
Date last updated
28/06/2017

Titles & IDs
Public title
FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers
Scientific title
A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects
Secondary ID [1] 0 0
114422
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastroparesis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK1322888
Treatment: Drugs - Placebo

Experimental: Cohort 1 - GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)

Experimental: Cohort 2 - GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)


Treatment: Drugs: GSK1322888
1 mg, 5 mg or 25 mg capsule

Treatment: Drugs: Placebo
matching placebo capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse Events following single oral doses of GSK1322888
Timepoint [1] 0 0
1 week post dose
Primary outcome [2] 0 0
pharmacokinetics of GSK1322888 following single, oral doses
Timepoint [2] 0 0
48 h post dose
Secondary outcome [1] 0 0
gastric emptying of a radio-labeled test meal, as measured by the 13C-octanoic acid breath test following single oral doses of GSK1322888
Timepoint [1] 0 0
4 h
Secondary outcome [2] 0 0
dose/exposure response relationship for gastric emptying of a radio-labeled test meal, as measured by the 13C-octanoic acid breath test following single oral doses of GSK1322888
Timepoint [2] 0 0
48 h
Secondary outcome [3] 0 0
dose proportionality following single dose administration
Timepoint [3] 0 0
48 h
Secondary outcome [4] 0 0
steady-state PK based on single dose data
Timepoint [4] 0 0
28 h
Secondary outcome [5] 0 0
accumulation based on single dose data
Timepoint [5] 0 0
48 h
Secondary outcome [6] 0 0
ethnicity differences in safety, tolerability, pharmacokinetics, and pharmacodynamics between volunteers of Caucasian or Japanese ethnicity
Timepoint [6] 0 0
1 week

Eligibility
Key inclusion criteria
- AST, ALT, alkaline phosphatase and bilirubin < or =1.5xULN (isolated bilirubin
>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

- Healthy as determined by a responsible and experienced physician

- Male or female between 18 (20 for Japanese) and 65 years of age inclusive

- Male subjects with female partners of child-bearing potential must agree to use one of
the contraception methods

- Body weight > or = 50 kg and BMI within the range 18.5 - 29.9 kg/m2 (inclusive).

- Capable of giving written informed consent

- Average QTc, QTcB or QTcF < 430 msec.

- For Japanese subjects Japanese ancestry defined as being born in Japan, having four
ethnic Japanese grandparents, holding a Japanese passport or identity papers and being
able to speak Japanese.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Hepatitis B or Hepatitis C positive

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones).

- A positive pre-study drug/alcohol screen.

- HIV positive

- History of regular alcohol consumption within 6 months of the study

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
potential enzyme inducer) prior to the first dose of study medication

- History of sensitivity to any of the study medications, or components thereof

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- Pregnant females

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

- Regular use of tobacco- or nicotine-containing products within 6 months prior to
screening.

- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
to the first dose of study medication.

- Subjects will be screened such that those subjects exhibiting rapid gastric emptying
rates (t½b < 75 min) will be excluded

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/11/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/03/2011
Sample size
Target
Accrual to date
Final
17
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Randwick
Recruitment postcode(s) [1] 0 0
2031 - Randwick

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is the First Time In Human study for the motilin receptor agonist, GSK1322888.
GSK1322888 is a potent and selective small molecule motilin receptor agonist, distinct from
the motilide compound structures. The aims of this study are to assess the safety, tolerance,
and pharmacokinetics of single oral doses of GSK1322888 and to identify a well-tolerated and
safe dose that will accelerate gastric emptying of a 13C stable isotope-labeled test meal in
healthy volunteers.

The study will include assessment of ECGs, vital signs, safety laboratory sampling, adverse
events, pharmacokinetics, and the 13C-Octanoic Acid Breath Test to measure gastric emptying.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01294566
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01294566